Raising Awareness for Men’s Health and Prostate Cancer

Cancer can have many faces. Whether you want to grow a mustache or sport one for fun, join Onco360 as we help support Movember for prostate cancer awareness in November. We can help your prostate cancer patients with expert funding assistance, superior service, and a large portfolio of prostate cancer medications.

A diagnosis unlike any other deserves a pharmacy unlike any other

As a specialty pharmacy focused on prostate cancer, we provide ongoing and personalized support including medication adherence, side effect management, and expert funding assistance.

We secured over $40 million in funding assistance for prostate cancer patients in 2021, including those on medications like Zytiga and Abiraterone. If you have any patients that are on the Zytiga free drug program that is
ending on December 30, 2022, Onco360 can help evaluate options available to your patients.

90% of prostate cancer patients paid less than $50 out of pocket on their last dispense

Currently, 85% of prostate cancer patient’s copays are covered by third-party funding sources or copay cards

3.5 days average time to first fill

We are Unmatched in Prostate Cancer Pharmacy Care

  • #1 in patient and provider satisfaction*
  • Innovative and personalized prostate MTM programs for eligible patients
  • Clinical programs developed by Board-Certified Oncology Pharmacists
  • Free Overnight delivery to a patient’s doorstep

Onco360 dispenses these prostate cancer and urology medications**


Casodex® (bicalutamide)
Erleada® (apalutamide)
Firmagon® (degarelix)
Jevtana® (cabazitaxel)
Keytruda® (pembrolizumab)
Lupron® (leuprolide)
Nubeqa® (darolutamide)
Orgovyx® (relugolix)
Taxotere® (doxetaxel)
Trelstar® (triptorelin)
Xtandi® (enzalutamide)
Yonsa® (abiraterone acetate, micronized)
Zytiga® (abiraterone acetate)

Refer Today

Limited Distribution Oncology Medications


Oncomed Dba Onco360 or
NPI# 1679618151

VONJO™ (pacritinib) for Myelofibrosis



How to Refer

*Third-party survey data provided by MMIT for Independent Specialty Pharmacies (Oncology). Report dates Q3 & Q4 2021.
**This list is a small portion of the comprehensive medications Onco360 can provide